Barclays Reiterates Overweight Rating on Twist Bioscience Corporation (TWST)

Market Context

Twist Bioscience Corporation operates in the Healthcare sector. The stock currently trades at $91.35 with a market capitalization of $1.9B.

Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Twist Bioscience Corporation.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Twist Bioscience Corporation

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jun 24, 2026	Barclays	Overweight	N/A
Jun 15, 2026	Canaccord Genuity	Buy	N/A
Jun 15, 2026	TD Cowen	Buy	N/A
Jun 11, 2026	Piper Sandler	Overweight	N/A
May 05, 2026	Barclays	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View TWST Stock Page